OROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery Or Not.
Recruiting
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 700
Inclusion Criteria
Recurrence of epithelial ovarian cancer, after first line chemotherapy with a disease-free interval of at least 6 months, age> 18 years, WHO Performance status 0-2. The first-line therapy should have consisted of at least 4 courses of either cisplatin or carboplatin.
Exclusion Criteria
More than one line chemotherapy, complete bowel obstruction, metastasized carcinoma (other tumor), leptomeningeal or brain metastases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival.
- Secondary Outcome Measures
Name Time Method Survival, toxicity, surgical treatment related complications and quality of life.